Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia

Torres, Harrys A.; Aguilera, Elizabeth; Mattiuzzi, Gloria; Cabanillas, Maria E.; Rohatgi, Nidhi; Sepulveda, Carmen A.; Kantarjian, Hagop; Jiang, Ying; Safdar, Amar; Raad, Issam; Chemaly, Roy F.

doi:10.3324/haematol.11300

Cited by 51 publications

(47 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…LRTI was defined as respiratory symptoms in patients with laboratory-confirmed RSV infection on nasal washes with new or changing pulmonary infiltrates as seen on chest radiographs or computed tomography scans that were suggestive of a viral etiology (ie, interstitial infiltrates, ground glass opacities) and with or without evidence of RSV in lower respiratory tract samples (eg, endotracheal tube aspirate, sputum, bronchoalveolar lavage fluid). 2,18 Death from all causes was assessed within 90 days after diagnosis of RSV infection and was attributed to RSV if the patient had persistent or progressive RSV infection with respiratory failure at the time of death. Neutropenia was defined as an absolute neutrophil count (ANC) ,500/mL, and lymphocytopenia was defined as an absolute lymphocyte count (ALC) ,200/mL.…”

Section: Definitionsmentioning

confidence: 99%

Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections

Shah

Ghantoji

Ariza-Heredia

et al. 2014

Blood

125

172

View full text Add to dashboard Cite

We developed an immunodeficiency scoring index for respiratory syncytial virus (ISI-RSV) infection, based on a cohort of 237 allogeneic hematopoietic cell transplant (allo-HCT) recipients, that can predict the risk of progression to lower respiratory tract infection (LRTI) and RSV-associated mortality. A weighted index was calculated using adjusted hazard ratios for immunodeficiency markers. Based on the ISI-RSV (range, 0-12), patients were stratified into low (0-2), moderate (3-6), and high (7-12) risk groups. A significant trend of increasing incidence of LRTI and RSV-associated mortality was observed as the risk increased from low to moderate to high (P < .001). Patients in the high-risk group had the greatest benefit of ribavirin-based therapy at the upper respiratory tract infection stage and the highest risk for progression to LRTI and death when antiviral therapy was not given (6.5 [95% confidence interval (CI), 1.8-23.6] and 8.1 [95% CI, 1.1-57.6], respectively). The ISI-RSV is designed to stratify allo-HCT recipients with RSV infection into groups according to their risk for progression to LRTI and RSVassociated mortality. Identification of high-risk groups using this index would distinguish patients who would benefit the most from antiviral therapy, mainly with aerosolized ribavirin. The ISI-RSV should be validated in a multiinstitutional study. (Blood. 2014;123(21):3263-3268)

show abstract

Section: Definitionsmentioning

confidence: 99%

Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections

Shah

Ghantoji

Ariza-Heredia

et al. 2014

Blood

125

172

View full text Add to dashboard Cite

show abstract

“…There was a trend toward a higher rate of progression from URTI to pneumonia in males compared to females (74% vs 56%). Viral and bacterial co-infections were diagnosed in nine (17%) of all patients five of which involved the lung (21). In a study performed between 2004 and 2009 on the molecular epidemiology of HRSV subgroups A and B in Irish adults with hematological malignancy, a total of 980 samples were evaluated for infection by this virus via immunofluorescence, from which 60 evaluable samples were HRSV-positive.…”

Section: Human Respiratory Syncytial Virus (Hrsv)mentioning

confidence: 99%

Viral Respiratory Infections in Patients with Cancer

Arjeyni

Goudarzi

Eslami

et al. 2017

Iranian Journal of Cancer Prevention

View full text Add to dashboard Cite

Context: Cancers are among the gravest causes of the intensive immunodeficiency and provide favorable conditions for severe respiratory tract infections. Evidence Acquisition: Using various keywords related to the subject matter, articles were analyzed in PubMed and appropriately selected for review. Results: In patients with cancer, some viral respiratory infections such as HRSV, Influenza virus, HCMV, HMPV and HPIV are prevalent. Conclusions: Viral respiratory infections in cancer patients are common and can worsen the patients' condition and disrupt the treatment process. Therefore, prevention and treatment of respiratory viral infections in cancer patients is important.

show abstract

“…RSV is also of clinical significance following allogeneic bone marrow transplantation and has been found in a substantial proportion of patients with lung infections [64,133]. Furthermore, RSV was responsible for 55% of fatal pneumonia cases in adult immunocompromised patients treated for lymphoma and leukemia in a retrospective study and was a major cause of viral pneumonia in several cohorts of patients with these hematological malignancies [57, 78, 81, 82, 164,201,228].…”

Section: Respiratory Syncytial Virusmentioning

confidence: 99%

Emerging Viral Infections

Schildgen

2010

Pulmonary Involvement in Patients With Hematological Malignancies

View full text Add to dashboard Cite

Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia

Cited by 51 publications

References 24 publications

Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections

Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections

Viral Respiratory Infections in Patients with Cancer

Emerging Viral Infections

Contact Info

Product

Resources

About